Asian Oncology Research Journal

Background and Objective: The study aims to evaluate the protective activity of 9-Diaminoacridine (N1-(acridin-9-yl) propane-1, 3-diamine hydrochloride; 9-DAAD) against Ehrlich Ascites Carcinoma (EAC) bearing mice.

Materials and Methods: A total forty mice were randomly divided into four groups (1^st group, control mice were injected with 0.1% DMSO 15 ml/ Kg bw subcutaneously; 2^nd group, mice were administered with 9-DAAD (30 mmol/ kg bw every 3 day) subcutaneously for 2 weeks; 3^rd group, mice were injected interaperitonealy with 2.5×10⁶ EAC cells/mouse; 4^th group, were injected with EAC as the 3^rd group then administered with 9-DAAD for another 2 weeks).

Results: The results showed that; EAC exhibit a significant reduction in RBCs, Hb, HCT, MCV, MCH, MCHC levels. Moreover, EAC exhibit a significant elevation in WBCs and PLT levels when compared to the control group.

Many histopathological alterations were observed within the splenic tissue of the EAC group as cellular degeneration of red and white pulps, several necrotic cells, vacuolar degeneration, and notable amyloid deposition. In addition, there is a significant increase in the activity of caspase-3 and vascular endothelial growth factor (VEGF) expressions. On the other hand; treatment of EAC mice with 9-DAAD regularized serum levels of the above-mentioned parameters and also restore the splenic tissue normal histological architecture.

Conclusion: The results indicated that the 9-DAAD possesses a protective activity against EAC induced changes in blood, biochemical parameters and splenic injury. Further studies are warranted to explore its mode of action and safety for medicinal use in cancer therapy.